| Literature DB >> 28435252 |
Yasamin Davatgaran-Taghipour1,2, Salar Masoomzadeh3, Mohammad Hosein Farzaei4,5, Roodabeh Bahramsoltani6, Zahra Karimi-Soureh7, Roja Rahimi6,8, Mohammad Abdollahi9,10.
Abstract
Cancer is defined as the abnormal cell growth that can cause life-threatening malignancies with high financial costs for patients as well as the health care system. Natural polyphenols have long been used for the prevention and treatment of several disorders due to their antioxidant, anti-inflammatory, cytotoxic, antineoplastic, and immunomodulatory effects discussed in the literature; thus, these phytochemicals are potentially able to act as chemopreventive and chemotherapeutic agents in different types of cancer. One of the problems regarding the use of polyphenolic compounds is their low bioavailability. Different types of formulations have been designed for the improvement of bioavailability of these compounds, nanonization being one of the most notable approaches among them. This study aimed to review current data on the nanoformulations of natural polyphenols as chemopreventive and chemotherapeutic agents and to discuss their molecular anticancer mechanisms of action. Nanoformulations of natural polyphenols as bioactive agents, including resveratrol, curcumin, quercetin, epigallocatechin-3-gallate, chrysin, baicalein, luteolin, honokiol, silibinin, and coumarin derivatives, in a dose-dependent manner, result in better efficacy for the prevention and treatment of cancer. The impact of nanoformulation methods for these natural agents on tumor cells has gained wider attention due to improvement in targeted therapy and bioavailability, as well as enhancement of stability. Today, several nanoformulations are designed for delivery of polyphenolic compounds, including nanosuspensions, solid lipid nanoparticles, liposomes, gold nanoparticles, and polymeric nanoparticles, which have resulted in better antineoplastic activity, higher intracellular concentration of polyphenols, slow and sustained release of the drugs, and improvement of proapoptotic activity against tumor cells. To conclude, natural polyphenols demonstrate remarkable anticancer potential in pharmacotherapy; however, the obstacles in terms of their bioavailability in and toxicity to normal cells, as well as targeted drug delivery to malignant cells, can be overcome using nanoformulation-based technologies, which optimize the bioefficacy of these natural drugs.Entities:
Keywords: anthocyanin; flavonoid; malignancy; natural products; tumor
Mesh:
Substances:
Year: 2017 PMID: 28435252 PMCID: PMC5388197 DOI: 10.2147/IJN.S131973
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Polyphenols with anticancer activity and their mechanisms of action
| Phytochemical category | Phytochemical name | Nanoformulation | Cell line/animal model | Anticancer activity | Reference |
|---|---|---|---|---|---|
| Coumarin | 4-Methyl-7-hydroxy coumarin | PLGA nanoparticles | Melanoma A375 cells | ↓Cell viability | |
| Farnesiferol C | Dendrosomal nanoparticles | AGS gastric cancer cell line | ↓Proliferation | ||
| Diarylheptanoid | Curcumin
| PLGA nanoparticles | CaSki and SiHa cervical cancer cells | ↓Cell growth | |
| MPEG-PLA-PAE nanoparticles | Human breast cancer MCF-7 cells | ↑Curcumin uptake | |||
| PLGA nanoparticles | Cisplatin-resistant A2780CP ovarian cancer cells | ↓Bcl-XL and Mcl-l | |||
| PLGA nanoparticles | Human colorectal cancer HCT116 cells | ↑Apoptosis by G2/M phase cell cycle arrest | |||
| PLGA nanoparticles | Cisplatin-resistant A2780CP ovarian cancer and metastatic MDA-MB-231 breast cancer cells | ↑Apoptosis | |||
| PNIPAAm-COOH nanoparticles | Human prostate cancer PC3, human breast cancer MCF-7 cells, and human nasopharyngeal cancer KB cells | ↑Curcumin uptake | |||
| Cyclodextrin/cellulose nanocrystals | Human prostate cancer PC-3 and DU145, as well as human colorectal carcinoma HT-29 cells | ↑Curcumin uptake | |||
| Folate-modified PLA-PEG micelles | Human hepatocellular carcinoma HepG2 cells | ↓Cell growth | |||
| PLGA nanoparticles by conjugation with anti-P-glycoprotein | Human cervical carcinoma KB-VI and KB-3-1 cells | ↑Curcumin uptake | |||
| Dextran micelles | C6 glioma cells | ↑Curcumin uptake | |||
| Dendrosomal nanoparticles | BALB/c metastatic breast cancer in mice | ↓Tumor size | |||
| F68-Cis-curcumin conjugate micelles | Human ovarian carcinoma A2780 and hepatocellular carcinoma SMMC 7721 cells | ↓MMP | |||
| PLGA nanoparticles | Diethylnitrosamine-induced hepatocellular carcinoma in Swiss albino rat | ↑Apoptosis | |||
| PCL nanodroplets | S180 cancer-bearing mice | ↓Tumor growth | |||
| PHEMA nanoparticles | Ovarian cancer SKOV-3 cells | ↓Tumor growth | |||
| Colloidal nanoparticles | Esophageal Barrett cancer OE19 and OE33 cells | ↓Proliferation in cancerous cells but not in normal cells | |||
| Nanoparticles prepared by ultrasonic spray | Human embyronic kidney HEK and human PC3 prostate cancer cells | ↓Cell viability (more obvious on HEK cells) | |||
| Nanostructured lipid carriers | Human neuroblastoma LAN5 cells | ↓Cell viability | |||
| Polymer–coated magnetic nanoparticles | Human ovarian carcinoma SKOv-3 cells | ↓Cell viability | |||
| Lipid-polymer hybrid nanoparticles in combination with docetaxel | Human PC3 prostate adenocarcinoma cells, BALB/c nude mice | ↑Adherence ability of the nanocarriers to cell membrane in PC3 | |||
| Flavonoid | Baicalein
| Paclitaxel–baicalein dual-targeted ligands of folate and hyaluronic acid | Human lung cancer A549 and drug-resistant lung cancer A549/PTX cells, xenograft mouse model of A549/PTX drug-resistant human lung cancer | ↓Cell viability | |
| Chrysin
| Nanosuspension | Human hepatocellular carcinoma HepG2 cells | ↓Cell growth | ||
| EGCG
| Ca/AlNO3-layered double-hydroxide nanoparticles | Human prostate cancer PC-3 cells | ↑Apoptosis | ||
| Chitosan nanoparticles | Human melanoma Mel 928 cells, xenograft athymic nu/nu mouse model of melanoma | ↓Apoptosis | |||
| EGCG (+ paclitaxel) | Core–shell PLGA–casein nanoparticles in targeted and nontargeted form | Human breast cancer MDA-MB-231 and MCF-7 cells, breast cancer cells isolated from patients | ↑Apoptosis | ||
| Green tea polyphenols | Graphene nanosheets | Colon cancer HT29 and Sw48 cells | ↑Photothermal destruction of Sw48 | ||
| Luteolin
| Phytosome | Human MDA-MB-231 breast cancer cells | ↓Cell viability | ||
| PLA-PEG-OMe nanoparticles | Lung cancer H292 cells, squamous cell carcinoma of head-and-neck Tu212 cells, xenograft mouse model of head and neck cancer | ↓Tumor growth | |||
| Quercetin
| Phytosome | Human breast cancer MCF-7 cells | ↑Apoptosis | ||
| Liposome | Human breast cancer MCF-7 cells | ↓Cell proliferation | |||
| Flavonolignan | Silibinin (+ glycyrrhizic acid)
| Pegylated nanoliposomes | Human hepatocellular carcinoma HepG2 cells | ↑Cell viability in cancerous cells but not in normal cells | |
| Lignan | Honokiol
| MPEG micelles | Mouse Lewis lung cancer cell lines LL/2 | ↓Cell growth | |
| Naphthoquinone | Plumbagin
| Silver nanoparticles | Human skin HaCaT and A431 cells | ↑Pyruvate kinase activity (more obvious in A431) | |
| Stilbene | Resveratrol
| PLGA-PEG-COOH nanoparticles | Human prostate cancer DU-145, PC-3, and LNCaP cells | ↑Cell growth and proliferation | |
| PCL nanocapsules | Murine melanoma B16F10 cells | ↓Tumor growth | |||
| Pegylated coencapsulation with 5-FU | Human NT8e head and neck cancer | Synergistic antineoplastic effect at high concentrations and antagonistic effect at low concentrations of resveratrol | |||
| Bovine serum albumin | Human ovarian cancer SKOV3 cells | ↑Apoptosis |
Abbreviations: ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CAT, catalase; cyt c, cytochrome c; 5-FU, 5-fluorouracil; GSH, glutathione; HPV, human papillomavirus; IL, interleukin; iNOS, inducible nitric oxide synthase; miRNA, microRNA; MMP, mitochondrial membrane potential; MPEG, methoxy polyethylene glycol; MPEG-PLA-PAE, (MPEG)-poly(lactide)-poly(b-amino ester); OMe, methoxy group; PAE, poly(b-amino ester); PARP, poly(ADP-ribose) polymerase; PCL, poly(ε-caprolactone); PEG, polyethylene glycol; pegylated, conjugated with PEG; PHEMA, poly(2-hydroxyethyl methacrylate); PLA, polylactic acid; PLGA, poly(lactic-co-glycolic acid); PNIPAAm, poly(N-isopropylacrylamide); ROS, reactive oxygen species; SOD, superoxide dismutase; TNF, tumor necrosis factor.
Advantages and disadvantages of conventional formulations versus nanoformulations
| Nanoformulations
| Conventional formulations
| ||
|---|---|---|---|
| Advantages | Disadvantages | Advantages | Disadvantages |
| Higher surface area-to-volume ratio | Short shelf life | Specified safety profile, predictable toxicity, stability, and pharmacokinetics | Untargeted drug delivery |
| Improved bioavailability | More expensive | Less expensive | Undesirable pharmacokinetics |
Figure 1Polyphenol nanoformulations and their mechanisms as antineoplastic agents.
Abbreviations: Casp-3 and -9, caspase-3 and caspase-9; MAPK/ERK, mitogen-activated protein kinases/extracellular signal-regulated kinases.